MINI FUTURE LONG - UNITED THERAPEUTICS Share Price

Certificat

DE000MG230D6

Market Closed - Börse Stuttgart 20:48:16 07/06/2024 BST
10.01 EUR -0.60% Intraday chart for MINI FUTURE LONG - UNITED THERAPEUTICS
Current month+2.04%
1 month+7.29%
Date Price Change
07/06/24 10.01 -0.60%
06/06/24 10.07 -0.40%
05/06/24 10.11 +4.55%
04/06/24 9.67 -2.52%
03/06/24 9.92 +1.12%

Delayed Quote Börse Stuttgart

Last update June 07, 2024 at 08:48 pm

More quotes

Static data

Product typeKnock-Out with Stop Loss
Buy / SellCALL
Underlying UNITED THERAPEUTICS CORPORATION
Issuer Morgan Stanley
WKN MG230D
ISINDE000MG230D6
Date issued 10/04/2024
Strike 167.8 $
Maturity Unlimited
Parity 10 : 1
Emission price 5.8
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 10.28
Lowest since issue 6.24

Company Profile

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Sector
-
More about the company

Ratings for United Therapeutics Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: United Therapeutics Corporation

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
275 USD
Average target price
294.2 USD
Spread / Average Target
+6.97%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW